Bayer Pharma AG

Thrombosis News Ticker

  • CHADS₂ Flags Atrial Fibrillation in Noncardiac Patients

    The CHADS₂ index, developed to gauge stroke risk in patients with atrial fibrillation, can also predict postoperative afib in noncardiac patients undergoing thoracic or vascular surgery, according to a study presented here at the Society of Critical Care Medicine 44th Critical Care Congress.

  • Rivaroxaban Shows Advantage Over Warfarin in Ca Patients

    Rivaroxaban was found to be as effective as sequential use of enoxaparin and warfarin for the prevention of recurrent venous thromboembolism (VTE) but safer, in two Phase III studies. Administered in a fixed dose, rivaroxaban, unlike enoxaparin and warfarin, does not require monitoring and dose adjustments based on prothrombin time.

  • Steroid Therapy Increases Risk of Blood Clots Five-Fold in IBD Patients

    Compared with biologic therapy, corticosteroid (steroid) use is associated with a nearly five-fold increase of venous thromboembolism in inflammatory bowel disease (IBD) patients, according to a new study in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association. Venous thromboembolism is a condition that includes both deep vein thrombosis and pulmonary embolism.

  • Inflammatory rheumatic diseases raise venous thromboembolism risk

    Individuals with inflammatory rheumatic diseases such as inflammatory arthritis, vasculitis, and connective tissue diseases, have a threefold increase in the risk of venous thromboembolism, compared with the general population, according to a meta-analysis.

  • NSAIDS users see an increased risk of venous thrombosis, study shows

    Some non-steroidal anti-inflammatory drugs (NSAIDs) increase the risk of arterial thrombosis. New findings from a systematic review and meta-analysis suggests that NSAIDs also increase the risk of venous thrombosis.

  • Epidemiology, Consequences of Non-Leg VTE in Critically Ill Patients

    Non-leg VTE was associated with a higher risk of pulmonary embolism during hospitalization, longer ICU stays.

  • New guidance on antithrombotic use in AF patients with ACS

    A new European joint consensus document on the use of antithrombotic drugs, including the non-vitamin K antagonist oral anticoagulants (NOACs), in patients with atrial fibrillation (AF) presenting with an acute coronary syndrome (ACS) and undergoing PCI is published today in the European Heart Journal.

  • Post-Surgery Atrial Fibrillation in Hospitalized Patients Is Associated with Increased Stroke Risk

    New research suggests that patients who develop seemingly temporary cases of atrial fibrillation (AF) immediately after most types of surgery are dramatically more likely to suffer subsequent strokes.

  • Ablation increases survival for adults with atrial fibrillation

    Adults who undergo a minimally invasive technique to treat atrial fibrillation are significantly less likely to die from a heart attack or heart failure, according to a long-term study by the University of Michigan Frankel Cardiovascular Center.

  • Rivaroxaban Beats Injectable on Cost-Effectiveness

    Rivaroxaban was more cost-effective than other anticoagulants for inpatient use in two retrospective studies that included patients undergoing joint replacement as well as those with atrial fibrillation or venous thromboembolism.

  • ESC Congress 2014 focuses on innovations in cardiology

    Innovative treatment approaches featured in the hot lines include vagal stimulation for systolic heart failure (NECTAR-HF), nitric oxide inhalation to reduce reperfusion injury in STEMI (NOMI) and the novel anti-Xa rivaroxaban for cardioversion (X-VERT).

  • Thromboembolic and Cardiovascular Risk in Rheumatoid Arthritis

    Circumstantial evidence suggests that the innate immune system and coagulation system share a common evolutionary origin, which explains the extensive crosstalk between inflammatory cytokines and coagulation factors, with many components being important for both systems.

  • First guidelines issued to prevent stroke in women

    Just as heart attack symptoms may differ between men and women, so do stroke risks. Now, the American Heart Association has issued its first guidelines for preventing strokes in women. They focus on birth control, pregnancy, depression and other risk factors that women face uniquely or more frequently than men do.

  • Antithrombin Deficiency Ups Risk for Recurrent VTE

    Patients who have inherited antithrombin (AT) deficiencies face an increased risk for recurrent episodes of venous thromboembolism (VTE), according to a recent study by Italian researchers.

  • Diabetes Risk Grows as Heart Failure Worsens

    Worsening heart failure severity -- indicated by increasing doses of loop diuretics -- was associated in a dose-dependent manner with rising risks of developing diabetes, a Danish study showed.

  • Hospitalizations and health care costs for atrial fibrillation 'on the rise'

    Approximately 2.7 million Americans have atrial fibrillation - a form of arrhythmia that can lead to other heart complications, such as stroke. Now, new research finds that hospitalizations related to the condition are on the rise, as are costs to treat it.

  • CABG Achieves Better 30-Day Outcomes vs PCI in Younger Patients, Similar 5-year Mortality

    Patients age 50 or younger have excellent and comparable immediate outcomes after undergoing either coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) with similar long-term survival, according to a study published online May 5, 2014, ahead of print in the American Journal of Cardiology. However, for patients with ST-segment elevation myocardial infarction (STEMI), long-term survival was better with PCI.

  • Bleeding risk increased in patients with cancer-associated VTE, chronic kidney disease

    Patients with cancer-associated venous thromboembolism and chronic kidney disease were at increased risk for major bleeding during anticoagulant treatment, according to study results.

  • ACE Inhibitors, ARBs Lower AF Risk in Hypertension

    Results from a large retrospective study suggest that controlling the activation of the renin-angiotensin system (RAS) with antihypertensive medications reduces the risk of atrial fibrillation.

  • Factor Xa inhibitor antidote shows promise in phase 2 study

    New phase 2 data presented at the American Society of Hematology Annual Meeting demonstrate that andexanet alfa effectively reversed the anticoagulation activity of rivaroxaban.